Location: United States, California, South San Francisco
Investors 1
| Date | Name | Website |
| - | Horizon Te... | horizontec... |
Mentions in press and media 25
| Date | Title | Description |
| 04.09.2024 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IPXX, PWUP, DECA, TTNP on Behalf of Shareholders | NEW YORK, Sept. 4, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders rela... |
| 12.03.2024 | Opioid Use Disorder Market to Reach USD 6.15 Billion by 2030, Driven by Growing Focus on Addiction Treatment | Opioid Use Disorder (OUD) Market Opioid Use Disorder Market Analysis, Industry Trends and Growth Outlook AUSTIN, TEXAS, UNITED STATES, March 12, 2024 /EINPresswire.com/ -- The global opioid use disorder market is experiencing significant gr... |
| 02.02.2022 | Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market | SOUTH SAN FRANCISCO, Calif., Feb. 2, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a securities purchase agreement with a single insti... |
| 21.12.2021 | Titan Pharmaceuticals to Explore Strategic Alternatives | SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has commenced a process to explore and evaluate strategic alternati... |
| 09.11.2021 | Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021 | SOUTH SAN FRANCISCO, Calif., Nov. 8, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, in a presentation given today at the Society for Neuroscience 2021 Meeting, ... |
| 05.11.2021 | Titan Announces Upcoming TP-2021 Implant Data Presentation at Neuroscience 2021 | SOUTH SAN FRANCISCO, Calif., Nov. 5, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. announced that data from continuing studies of its ProNeura®-based TP-2021 implant in an established animal model of chronic pruritus will be presented at... |
| 25.10.2021 | Titan Pharmaceuticals : Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries | SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has received funding from the Bill & Melinda Gates Foundation t... |
| 12.10.2021 | Titan Pharmaceuticals : and MUSC FRD Enter Into Research and Option License Agreement | SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a research and option license agreement (the "... |
| 23.06.2021 | Titan Pharmaceuticals : Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus | SOUTH SAN FRANCISCO, Calif., June 23, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," formerly JT-09) ProNeura®-based im... |
| 23.06.2021 | Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus |
Show more